Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | GSR | P00390 | 1/20 | 0.38 |
| ▸ | CPB2 | Q96IY4 | 7/20 | 0.38 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 1/20 | 0.37 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.35 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.35 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22859968 | 1.00 | FOLH1 (0.40) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL10047161 | 1.00 | FOLH1 (0.40) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL19483433 | 0.98 | CPB2 (0.41) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL19483432 | 0.98 | CPB2 (0.41) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL19483311 | 0.96 | FOLH1 (0.37) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL19483319 | 0.96 | FOLH1 (0.37) | FOLH1GSRCPB2SIRT6SIRT1 | |
| SCHEMBL19483323 | 0.89 | GABRR1 (0.34) | — | |
| SCHEMBL19483318 | 0.89 | GABRR1 (0.34) | — | |
| SCHEMBL25767678 | 0.89 | NMT1 (0.40) | FOLH1CPB2SIRT6SIRT1 | |
| SCHEMBL23016394 | 0.88 | CPB2 (0.39) | FOLH1GSRCPB2SIRT6SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4245864-A1 | CHIP, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | GeneMind Biosciences Company Limited (CN) | 2023-09-20 | — | — | EP | disclosed |
| EP-4198144-A1 | AMINO-MODIFIED CHIP, PREPARATION METHOD THEREFOR AND USE THEREOF | GeneMind Biosciences Company Limited (CN) | 2023-06-21 | — | — | EP | disclosed |
| WO-2023003515-A2 | FUNCTIONALISED POLYPEPTIDES, NANOPARTICLES AND USES THEREOF | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-01-26 | — | — | WO | disclosed |
| US-11058775-B2 | Insulin dimer-incretin conjugates | MERCK SHARP & DOHME CORP. (US) | 2021-07-13 | — | — | US | disclosed |
| WO-2021064774-A1 | HIGH MOLECULAR WEIGHT REDOX POLYMER AND BIOSENSOR USING SAME | ＰＨＣホールディングス株式会社 | 2021-04-08 | — | — | WO | disclosed |
| US-10626144-B2 | Peptide derivatives and uses thereof | NOSOPHARM (FR) | 2020-04-21 | — | — | US | disclosed |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-27 | — | — | US | disclosed |
| US-20190175744-A1 | INSULIN-INCRETIN CONJUGATES | MERCK SHARP & DOHME CORP. (US) | 2019-06-13 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | NOSOPHARM (FR) | 2017-10-19 | — | — | US | disclosed |
| US-20170092865-A1 | N-TYPE ORGANIC SEMICONDUCTOR FORMULATIONS AND DEVICES | YUNING LI (CA) | 2017-03-30 | — | — | US | disclosed |
| US-20090105179-A1 | DRUG CARRIERS | NITTO DENKO CORPORATION (JP) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190175744-A1 | INSULIN-INCRETIN CONJUGATES | GIPR, GLP1R, GCGR | FOLH1 320/4885GSR 976/4885CPB2 1003/4885 |
| US-10626144-B2 | Peptide derivatives and uses thereof | VIP, IAPP, NGLY1 | FOLH1 138/4885GSR 3570/4885CPB2 236/4885 |
| US-20190192675-A1 | INSULIN DIMER-INCRETIN CONJUGATES | IAPP, GLP1R, GIPR | FOLH1 175/4885GSR 4015/4885CPB2 243/4885 |
| US-11058775-B2 | Insulin dimer-incretin conjugates | IAPP, GLP1R, GIPR | FOLH1 175/4885GSR 4015/4885CPB2 243/4885 |
| US-20090105179-A1 | DRUG CARRIERS | HDGF, FIBP, SLC47A2 | FOLH1 114/4885GSR 1599/4885CPB2 895/4885 |
| US-20170298097-A1 | Peptide Derivatives and Uses Thereof | VIP, IAPP, NGLY1 | FOLH1 138/4885GSR 3570/4885CPB2 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.